SCHEMBL2677945

SCHEMBL2677945

COCCN1CCN(Cc2c(C(=O)O)c3ccccc3c(=O)n2-c2ccccc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P4HB P07237 1/20 0.44
MAPT P10636 3/20 0.43
ALDH1A1 P00352 4/20 0.41
LMNA P02545 3/20 0.41
GAA P10253 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NPSR1 Q6W5P4 4/20 0.40
TSHR P16473 1/20 0.40
HTR7 P34969 6/20 0.39
DRD2 P14416 3/20 0.38
DRD3 P35462 3/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2677324 0.88 MAPT (0.51) P4HBMAPTALDH1A1LMNAGAA
SCHEMBL2677354 0.87 P4HB (0.44) P4HBMAPTALDH1A1KDM4EHSD17B10
SCHEMBL2675238 0.86 P4HB (0.51) P4HBMAPTALDH1A1LMNAGAA
SCHEMBL2677561 0.86 ALDH1A1 (0.42) P4HBMAPTALDH1A1LMNAKDM4E
SCHEMBL2675784 0.85 ALDH1A1 (0.44) P4HBMAPTALDH1A1LMNAKDM4E
SCHEMBL2675780 0.85 ALDH1A1 (0.48) P4HBMAPTALDH1A1LMNAGAA
SCHEMBL3631253 0.85 P4HB (0.44) P4HBMAPTNPSR1TSHRHTR7
SCHEMBL1717920 0.85 P4HB (0.42) P4HBMAPTALDH1A1LMNAGAA
SCHEMBL2675946 0.84 P4HB (0.45) P4HBMAPTALDH1A1NPSR1HTR7
SCHEMBL2676679 0.84 NPSR1 (0.50) P4HBMAPTALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 P4HB 3494/4885MAPT 3659/4885ALDH1A1 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.